July 3, 2026
Perseus Proteomics Inc.
President & CEO: Takuya Yokokawa
e-mail: ir@ppmx.com

Receives Notice of Allowance in the U.S. for Patent Application Relating to the Therapeutic Use of PPMX-T003 for Polycythemia

Perseus Proteomics Inc. announces that it has received a Notice of Allowance* from the United States Patent and Trademark Office (USPTO) for its patent application relating to the use of PPMX-T003, an anti-transferrin receptor 1 antibody currently under development by the Company, as a therapeutic agent for polycythemia.

Title of Invention: Therapeutic Agent for Polycythemia
Application No.: 17/640,645
International Application No. PCT/JP2020/033561, filed on September 4, 2020
Applicants: Perseus Proteomics Inc. and Juntendo Educational Incorporated

The patent application for which the Notice of Allowance has been received covers, within a certain scope, the use of PPMX-T003 as a therapeutic agent for polycythemia, including polycythemia vera.

The patent application has been filed in Japan, the United States, Europe, China and Hong Kong, and patents have already been granted in Japan and China. The Company has now received a Notice of Allowance in the United States.

The receipt of this Notice of Allowance is not expected to have any impact on the Company's financial results for the current fiscal year. However, the Company expects this allowance to contribute to enhancing its corporate value over the medium to long term through future business development.

End

Glossary

Notice of Allowance

A Notice of Allowance is an official notification issued when a patent office determines, upon examination, that a patent application is allowable. After a Notice of Allowance is issued, the patent will be registered and patent rights will come into effect upon payment of the prescribed registration fee.